rosiglitazone 中文意思是什麼

rosiglitazone 解釋
羅格列酮
  1. To avoid unnecessary panic among patients, a calm - er and more considered approach to the safety of rosiglitazone is needed. alarmist headlines and confi - dent declarations help nobody

    為避免患者中不必要的驚恐，一個更平靜的和更慎重考慮的方法來考慮羅格列酮的安全性是需要的。警告性的標題和有信心的聲明不能幫助任何人。
  2. When rosiglitazone was first authorised in the eu in 2000, it was contraindicated in patients with a history of cardiac failure

    2000年歐盟首次批準使用羅格列酮時，就其應用於心衰病史患者身上就存在著爭議。
  3. Effects of rosiglitazone on insulin resistance in fructose - fed rats

    羅格列酮對高果糖大鼠胰島素抵抗的影響
  4. The influence of rosiglitazone maleate on the intima - media thickness of common carotid artery in type 2 diabetic patients

    馬來酸羅格列酮對2型糖尿病患者頸動脈內膜中層厚度的影響
  5. Effect of rosiglitazone on hypertension induced by 5 6 nephrectomy rats

    羅格列酮對腎大部切除大鼠腎性高血壓的影響
  6. Aandia is known generically as rosiglitazone, while actos is known as pioglitazone

    文迪雅的通用名為羅格列酮，艾可拓通用名為吡格列酮。
  7. In the fda hearing on rosiglitazone, several meta - analyses revealed a significant increase in the risk of myocardial ischemic events among patients taking rosiglitazone

    在fda的羅格列酮聽證會上，數個薈萃分析表明使用該藥的患者其心肌缺血事件的風險顯著增大。
  8. They and their patients have been very worried about the cardiovascular safety of rosiglitazone due to the meta analysis paper from new england journal of medicine

    因為最近在《新英格蘭醫學雜志》上發表的那篇薈萃分析，他們和他們的患者現在很擔心羅格列酮的心血管安全性問題。
  9. The combination with rosiglitazone and metformin is seemly a very nice combined therapy for glycemia control and reduction of adverse events ， i want to know if there evidence to reduce the postmeal glucose and fasting glucose, and other diabetes complication

    羅格列酮與二甲雙胍的聯合用藥看來是一種非常好的組合，可以有效控制血糖及減少不良事件，請您具體談一下關于這一聯合用藥有效控制餐前及餐后血糖及減少其他糖尿病並發癥的臨床證據。
  10. On july 30, 2007, the endocrinologic and metabolic drugs advisory committee and the drug safety and risk management advisory committee of the food and drug administration ( fda ) convened to discuss the myocardial ischemic risk associated with rosiglitazone treatment in patients with type 2 diabetes mellitus

    Fda的內分泌和代謝藥物顧問委員會及藥物安全和風險控制顧問委員會聚集一堂探討2型糖尿病患者使用羅格列酮的心肌缺血風險問題。
  11. " these findings have potential clinical implications, as they suggest that long - term rosiglitazone usage in the treatment of type 2 diabetes and insulin resistance may cause osteoporosis, owing to a combination of decreased bone formation and increased bone resorption, " the authors conclude

    作者總結認為，上述研究發現對于臨床治療具有潛在的意義， 2型糖尿病及胰島素耐受患者長期使用羅格列酮治療，可能通過抑制骨生成與促進骨的再吸收而導致骨質疏鬆
  12. The basic plot of the rosiglitazone story quickly became obvious to the advisory committee : a new " wonder drug, " approved prematurely and for the wrong reasons by a weakened and underfunded government agency subjected to pressure from industry, had caused undue harm to patients

    對于顧問委員會，羅格列酮事件的基本情節很快就一目了然：一個神奇的藥物，由一個權利削弱、資金不足而迫於企業壓力的機構過早地批準上市，最終對患者帶來了不必要的傷害。
  13. Effects of rosiglitazone on fatty liver induced by high fat diet in rats

    馬來酸羅格列酮干預高脂飼養大鼠脂肪肝的研究
  14. Moreover, we are facing a troubling paradox : preliminary data that were presented at the meeting and published by gerrits et al. 3 suggest that among the thiazolidinediones ? a class of drugs that has been shown to improve metabolic control ? rosiglitazone may increase cardiovascular risk whereas pioglitazone may reduce it

    進一步來講，我們正在面臨著一個矛盾的處境；初期的數據表明噻唑烷二酮類藥物（已經證實能夠改善代謝）里的羅格列酮會增加心血管風險，而同類的匹格列酮可以降低這種風險。
  15. During that time, women taking rosiglitazone were more likely to hae bone fractures than women taking either metformin or glyburide

    隨訪期間，羅格列酮組的女性患者骨折發生率明顯高於二甲雙胍組和格列本脲組。
  16. Effect of rosiglitazone on ovulation induction in women with polycystic ovary syndrome

    羅格列酮用於多囊卵巢綜合征促排卵治療的效果觀察
  17. And ( 2 ) among the anti - diabetic drugs currently registered in hong kong, two drugs belong to the ppar agonist class. the two drugs are rosiglitazone maleate ( avandia ) and pioglitazone ( actos )

    這兩種藥物為羅格列酮（ avandia ）和?格列酮（ actos ） ，分別於二年十一月及二一年六月在本港注冊。
  18. The contrasts among the levels of evidence and the results regarding the safety of rosiglitazone raised new questions about relative and absolute risks but also highlighted the weaknesses of observational studies examining events that are common and whose rates are likely to be increased only slightly by a given drug, even in a large cohort ( such as that used by wellpoint, which comprised 160, 000 patient records )

    這些涉及羅格列酮安全性的矛盾的證據也提出了絕對和相對風險的新問題，同時也更加突出了觀察性研究的缺陷，主要是在評估常見事件及明確特定藥物引起哪種事件輕度增加的環節方面。
  19. By contrast, when ppar - gamma activity was stimulated with rosiglitazone, a commonly used anti - diabetes agent, the animals displayed decreased bone density

    相反，羅格列酮（一種常用抗糖尿病藥物）刺激了ppar -的活性時，動物的骨密度顯示降低
  20. Anti - hypertensive effect of rosiglitazone in non - diabetic essential hypertension

    胰島素增敏劑羅格列酮抗高血壓作用探討
分享友人
分享到 Line

分享到臉書